These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35377003)

  • 1. Human Challenge Studies for Cholera.
    Cohen MB
    Curr Top Microbiol Immunol; 2022 Apr; ():. PubMed ID: 35377003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine.
    Cohen MB; Giannella RA; Bean J; Taylor DN; Parker S; Hoeper A; Wowk S; Hawkins J; Kochi SK; Schiff G; Killeen KP
    Infect Immun; 2002 Apr; 70(4):1965-70. PubMed ID: 11895960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea.
    Ahmed T; Bhuiyan TR; Zaman K; Sinclair D; Qadri F
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD009029. PubMed ID: 23828581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nontoxigenic Vibrio cholerae Challenge Strains for Evaluating Vaccine Efficacy and Inferring Mechanisms of Protection.
    Fakoya B; Hullahalli K; Rubin DHF; Leitner DR; Chilengi R; Sack DA; Waldor MK
    mBio; 2022 Apr; 13(2):e0053922. PubMed ID: 35389261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.
    Tacket CO; Cohen MB; Wasserman SS; Losonsky G; Livio S; Kotloff K; Edelman R; Kaper JB; Cryz SJ; Giannella RA; Schiff G; Levine MM
    Infect Immun; 1999 Dec; 67(12):6341-5. PubMed ID: 10569747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired immune response to natural infection as a correlate of vaccine failure in a field trial of killed oral cholera vaccines.
    Clemens J; Rao M; Sack D; Ahmed F; Khan MR; Chakraborty J; Kay B; Huda S; Yunus M; van Loon F
    Am J Epidemiol; 1995 Oct; 142(7):759-64. PubMed ID: 7572947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial.
    Sur D; Lopez AL; Kanungo S; Paisley A; Manna B; Ali M; Niyogi SK; Park JK; Sarkar B; Puri MK; Kim DR; Deen JL; Holmgren J; Carbis R; Rao R; Nguyen TV; Donner A; Ganguly NK; Nair GB; Bhattacharya SK; Clemens JD
    Lancet; 2009 Nov; 374(9702):1694-702. PubMed ID: 19819004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection.
    Losonsky GA; Tacket CO; Wasserman SS; Kaper JB; Levine MM
    Infect Immun; 1993 Feb; 61(2):729-33. PubMed ID: 8423098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a vaccine against experimental cholera and Escherichia coli diarrheal disease.
    Rappaport RS; Bonde G
    Infect Immun; 1981 May; 32(2):534-41. PubMed ID: 7019073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Field trial of oral cholera vaccines in Bangladesh.
    Clemens JD; Sack DA; Harris JR; Chakraborty J; Khan MR; Stanton BF; Kay BA; Khan MU; Yunus M; Atkinson W
    Lancet; 1986 Jul; 2(8499):124-7. PubMed ID: 2873397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of follow-up of a randomised trial.
    Qadri F; Ali M; Lynch J; Chowdhury F; Khan AI; Wierzba TF; Excler JL; Saha A; Islam MT; Begum YA; Bhuiyan TR; Khanam F; Chowdhury MI; Khan IA; Kabir A; Riaz BK; Akter A; Khan A; Asaduzzaman M; Kim DR; Siddik AU; Saha NC; Cravioto A; Singh AP; Clemens JD
    Lancet Infect Dis; 2018 Jun; 18(6):666-674. PubMed ID: 29550406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The design and analysis of cholera vaccine trials: recent lessons from Bangladesh.
    Clemens J; Sack D; Rao M; Chakraborty J; Kay B; Ahmed F; Khan MR; van Loon FP; Svennerholm AM; Holmgren J
    Int J Epidemiol; 1993 Aug; 22(4):724-30. PubMed ID: 8225749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers.
    Islam K; Hossain M; Kelly M; Mayo Smith LM; Charles RC; Bhuiyan TR; Kováč P; Xu P; LaRocque RC; Calderwood SB; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB; Qadri F; Ryan ET
    PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006376. PubMed ID: 29624592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
    García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
    Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam.
    Trach DD; Clemens JD; Ke NT; Thuy HT; Son ND; Canh DG; Hang PV; Rao MR
    Lancet; 1997 Jan; 349(9047):231-5. PubMed ID: 9014909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Cholera Conjugate Vaccine Containing O-specific Polysaccharide (OSP) of V. cholerae O1 Inaba and Recombinant Fragment of Tetanus Toxin Heavy Chain (OSP:rTTHc) Induces Serum, Memory and Lamina Proprial Responses against OSP and Is Protective in Mice.
    Sayeed MA; Bufano MK; Xu P; Eckhoff G; Charles RC; Alam MM; Sultana T; Rashu MR; Berger A; Gonzalez-Escobedo G; Mandlik A; Bhuiyan TR; Leung DT; LaRocque RC; Harris JB; Calderwood SB; Qadri F; Vann WF; Kováč P; Ryan ET
    PLoS Negl Trop Dis; 2015; 9(7):e0003881. PubMed ID: 26154421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fusion-expressed CtxB-TcpA-C-CPE improves both systemic and mucosal humoral and T-cell responses against cholera in mice.
    Souod N; Kargar M; Hoseini MH; Jafarinia M
    Microb Pathog; 2021 Aug; 157():104978. PubMed ID: 34022352
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.